Li, Yutao; Sharma, Amit; Maciaczyk, Jarek; Schmidt-Wolf, Ingo G. H. published the artcile< Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside>, Computed Properties of 112-63-0, the main research area is review glioblastoma NKT immunotherapy; blood–brain barrier; blood–brain tumor barrier; cytokine-induced killer cells; glioblastoma; immunotherapy; invariant NKT; overall survival; tumor infiltration lymphocytes.
A review. Glioblastoma multiforme (GBM) is an aggressive and dismal disease with a median overall survival of around 15 mo and a 5-yr survival rate of 7.2%. Owing to genetic mutations, drug resistance, disruption to the blood-brain barrier (BBB)/blood-brain tumor barrier (BBTB), and the complexity of the immunosuppressive environment, the therapeutic approaches to GBM represent still major challenges. Conventional therapies, including surgery, radiotherapy, and standard chemotherapy with temozolomide, have not resulted in satisfactory improvements in the overall survival of GBM patients. Among cancer immunotherapeutic approaches, we propose that adjuvant NKT immunotherapy with invariant NKT (iNKT) and cytokine-induced killer (CIK) cells may improve the clin. scenario of this devastating disease. Considering this, herein, we discuss the current strategies of NKT therapy for GBM based primarily on in vitro/in vivo experiments, clin. trials, and the combinatorial approaches with future therapeutic potential.
International Journal of Molecular Sciences published new progress about Blood-brain barrier. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Computed Properties of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics